BioWorld

Nov. 9, 2004

Medarex, BMS MDX-010 Deal: Payments Could Total $530M

Medarex Inc. could receive up to $530 million through a deal to partner a Phase III metastatic melanoma product with Bristol-Myers Squibb Co. (BioWorld Today) Read More

Full Confirmatory Phase III Data Strong, Says NitroMed

Study: Millennium's Integrilin Improves Myocardial Perfusion

Inpharmatica Raises £13.9M To Fuel Firm Until Profitability

Biogen Idec, Elan Unveil One-Year Antegren Data

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...